Kalbe Farma Tbk

Overview

KLBF Overview

PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritionals, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over the counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising of powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.

5101520ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: KLBF

Main
Market Cap.
IDR 72.62Trillion
#26 in Indonesia

~$4.46B USD

Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Sector
Healthcare

Valuation

KLBF Valuation Metrics

1,570

IDR
0.0%

Closing Price on 2024-07-18

Price to Equity

25.32

P/E

At 25.32x P/E TTM, KLBF.JK is trading at a premium to its peers in the Pharmaceuticals & Health Care Research sector (avg 10.2x).

Price to Book

3.24

P/B

At 3.24x P/B TTM, KLBF.JK is trading at a premium to its peers in the Pharmaceuticals & Health Care Research sector (avg 1.2x).

Price to Sales

2.35

P/S

At 2.35x P/S TTM, KLBF.JK is trading at a premium to its peers in the Pharmaceuticals & Health Care Research sector (avg 0.8x).

Valuing Kalbe Farma Tbk based on its trailing twelve months (TTM) valuation metrics against its peers in the Pharmaceuticals & Health Care Research sector

Historical Price to Earnings

Other Valuation Metrics

Valuing Kalbe Farma Tbk relative to other stocks in the Pharmaceuticals & Health Care Research sector

Price/Cash Flow18.55x
Price/Forward Earnings21.50x
Enterprise Value/Revenue2.23x
Enterprise Value/EBITDA16.53x
PEG Ratio2.13x

Intrinsic Value

Last closing: IDR1,5702024-07-18
IDR 913.09

Considerably Lower Intrinsic Value: Analyst's intrinsic value is of KLBF is IDR913, which is 41% lower than KLBF's last closing price of IDR1,570 (as of 2024-07-18).

Valuation Recap of KLBF stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of 25.32x is above the ID market average of 8.44x and is trading at a premium to peers in the Pharmaceuticals & Health Care Research sector (10.21x). In fact, less than 25% of its peers trade at a higher P/E ratio than KLBF.

High
The P/B ratio is calculated by dividing the market price of a company's stock by its book value per share (BVPS). It measures the company's stock value relative to its assets minus liabilities. A P/B ratio of 3.24x is above the peers average of 1.20x in the Pharmaceuticals & Health Care Research sector.

Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 2.35x is above the peers average of 0.80x in the Pharmaceuticals & Health Care Research sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of KLBF's valuation relative to its current sales and future earnings growth. KLBF trades at a Forward P/E ratio of 21.50x, which is considered richly valued by analysts.

Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. KLBF's P/CF ratio of 18.55x is considered a relatively high ratio by analysts.

Low
The Enterprise Value/Revenue ratio (EV/R) is calculated by dividing the enterprise value of a company by its revenue. It measures the company's enterprise value relative to its revenue. It is an indicator of how much it costs to buy the company's revenue; the lower the ratio, the cheaper the company's revenue. KLBF's EV/R ratio of 2.23x is considered fairly underpriced by the market. The average EV/R ratio for the Pharmaceuticals & Health Care Research sector is 1.12x.

Medium
Considerably Lower Intrinsic Value: Analyst's intrinsic value is of KLBF is IDR 913.09, which is 41% lower than KLBF's last closing price of IDR 1,570.00.

Peers

KLBF Peers and Comparison

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk72.62T28.96T 30.94T 2.87T 25.323.24
MIKAPT Mitra Keluarga Karyasehat Tbk.41.17T7.81T 4.48T 0.97T 42.256.74
SILOPT Siloam International Hospitals Tbk.34.40T11.42T 11.56T 0.98T 35.274.35
SRAJSejahteraraya Anugrahjaya Tbk27.60T5.62T 2.71T -0.02T -1387.8514.83
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk22.35T4.25T 3.71T 1.04T 21.475.89
HEALPT Medikaloka Hermina Tbk.19.88T9.20T 6.14T 0.52T 38.274.77
TSPCTempo Scan Pacific Tbk9.02T11.93T 13.33T 1.02T 8.881.11
PRAYPT Famon Awal Bros Sedaya Tbk8.52T4.81T 1.93T 0.21T 41.372.96
SOHOPT Soho Global Health Tbk8.50T5.13T 8.58T 0.44T 19.303.37
OMEDPT Jayamas Medica Industri Tbk5.14T2.65T 1.77T 0.27T 19.302.25
Competitiveness Recap of KLBF stock
WeightNotesScore
High
At a market cap of IDR 72,621.30 billion, KLBF.JK ranks 1 in Market Cap out of 10 companies in the Healthcare sector.

High
At a PE of 25.32, KLBF.JK ranks 5 out of 10 companies in the Healthcare sector for P/E value. The average PE is -113.64 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. In this regard, it trails behind sector leaders such as PT Mitra Keluarga Karyasehat Tbk. (42.25) in the Healthcare sector.

Medium
At a PE of 25.32, KLBF.JK is trading at a higher PE than that of its subsector peers in Pharmaceuticals & Health Care Research (median of 10.21). false

Medium
At a revenue of IDR 30.94 trillion, KLBF.JK ranks 1 in Revenue out of 10 companies in the Healthcare sector.

Medium
At a profit of IDR 2.87 trillion, KLBF.JK ranks 1 in Profit out of 10 companies in the Healthcare sector.

Future

Future Growth of KLBF

Growth Forecasts

Analyst Ratings

Based on ratings from 14 analysts for KLBF over the past 3 months.

Hold

Strong Buy

42.9%

Buy

7.1%

Hold

50.0%

Sell

0.0%

Strong Sell

0.0%

Last Update: 2024-07-10

Sector Benchmark

Pharmaceuticals & Health Care Research companies in Indonesia are growing at a projected rate of 14.83% against the IDX average of +13.8%.

Pharmaceuticals & Health Care Research sector overview

KLBF Earnings & Revenue Forecast

All values in IDR billion

Future growth prospect of KLBF
WeightNotesScore
High
KLBF's projected growth rate of 14.83% is above the ID market average of 13.82%.

High
The Pharmaceuticals & Health Care Research sub-sector is projected to grow revenue by 15.33% in 2025. This number is higher than the previous year 2024's growth rate of 6.68%. This bodes well for KLBF's revenue growth prospects in the next 2 years.

Medium
The Pharmaceuticals & Health Care Research sub-sector is projected to increase earnings by 16.41% in 2025. This number is higher than the previous year 2024's EPS growth of 5.49%. This bodes well for KLBF's earnings growth prospects in the next 2 years.

Medium
KLBF and its peers in the Pharmaceuticals & Health Care Research sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a fruitful year heading into 2025. Specifically, earnings are projected to increase by 17.62% in 2025 while revenue growth is projected to increase by 20.39%. These macroeconomic trends will likely be a tailwind for KLBF's earnings growth prospects in the next 2 years.

Technical

Daily Technical Ratings of KLBF

Oscillators

Neutral

Sell

2

Neutral

8

Buy

1

Summary

Buy

Sell

5

Neutral

9

Buy

12

Moving Averages

Strong Buy

Sell

3

Neutral

1

Buy

11

Summary

Technical Ratings of KLBF
IndicatorSummarySellNeutralBuy
SummaryBuy5912
OscillatorsNeutral281
Moving AveragesStrong Buy3111

Last Update: 2024-07-19

Loading...
Loading...

Management

Executive Management

President Director

Bernadette Ruth Irawati Setiady15.2 years
Sie DjohanDirector
MulialieDirector
Jos Iwan AtmadjajaDirector
Kartika SetiabudyDirector
NamePositionShares%Stock Value
(in Billion IDR)
MulialieDirector250,045< 0.010.39B
Ronny HadianaCommissioner92,671,0070.2145.49B

Ownership

KLBF Ownership

NameNumber of SharesOwnership (%)Value
Public (Scripless)18,852,691,03340.2229,598.72B
Ladang Ira Panen, Pt4,903,185,74010.467,698.00B
Gira Sole Prima, Pt4,824,509,48510.297,574.48B
Santa Seha Sanadi, Pt4,718,121,94010.077,407.45B
Diptanala Bahana, Pt4,454,807,0409.56,994.05B
Lucasta Murni Cemerlang, Pt4,439,895,4409.476,970.64B
Bina Arta Charisma, Pt3,844,639,0408.26,036.08B
Treasury Stock631,912,8001.35992.10B
Ronny Hadiana92,671,0070.2145.49B
Public (Scrip)90,850,5400.19142.64B
B. R. Irawati Setiady21,588,0000.0533.89B

Largest Institutional Buy

Capital Research and Management Company
Bought 31-12-2023
+73,750,000 shares
Capital Guardian Trust Company
Bought 31-12-2023
+24,750,000 shares
Capital International Inc
Bought 31-12-2023
+24,750,000 shares

Largest Institutional Sell

No data is available for KLBF at the moment.

Institutional Transactions

Tracking institutional transactions buying / selling of KLBF stock

Sustainability

Environmental, Social, and Governance (ESG) Risk Assessment

The ESG Risk Ratings measure KLBF's exposure to industry-specific material ESG risks and how well KLBF is managing those risks.

ESG Risk Rating

10
20
30
40
0
100

33.3

High Risk

Negligible

Low

Medium

High

Severe

ESG Risk Ranking among Pharmaceuticals Peers

1st rank = lowest risk

684

/ 921 peers worldwide

Global ESG Risk Ranking

13,096

/ 16,216 all companies worldwide

Top Material ESG Issues

  • Product Governance
  • Access to Basic Services
  • Business Ethics
  • Bribery and Corruption

Last Full Update: 2023-10-11

Last Update: 2024-05-23

Source: Sustainalytics, Inc.

KLBF Filings

No noteworthy filings to report on

    Sectors, Indonesia's Financial Data Layer

    We hate spam as much as you do. We do not resell your data.

    Email us at sectors@supertype.ai for enquiries on using Sectors for your organization.

    © 2024 Supertype Pte. Ltd.
    (and subsidiary PT. Supertype Teknologi Nusantara)